Clinical Trials

If you would like more information about any of these available clinical trials, or if you know a patient who you think would qualify, please call Jeanetta at 903-531-8850 or call our office at 903-597-CARE (2273).

Study List for Blood and Cancer Center of East Texas, March 8, 2012 

NSC Lung


An open-Label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-based Chemotherapy versus Platinum-based Chemotherapy Alone as First-Line Treatment of Patients with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Must have Stage 4 measurable disease
  • Can be squamous or nonsquamous
  • ECOG 0-2
  • Life expectancy of ≥ 3 months
  • There are 4 arms to this study the investigator can choose between Cisplatin and Carboplatin in all 4 arms.

Amgen 20070782:

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Evary-3-Weeks in Anemic Subjects with Advanced Stage Non-Small Cell Lung Cancer Receiving Multi-Cycle Chemotherapy
  • ECOG 0-1
  • HBG ≤ 11.0 g/dL
  • No brain mets



A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor – Positive and HER2-Negative Breast Cancer with Recurrence Score of 25 or Less. ( Opens in July 2011)
  • Must have 1-3 positive nodes
  • No inflammatory breast cancer
  • ECOG 0-2
  • No prior treatment for breast cancer


Connect CLL:

The Chronic Lymphocytic Leukemia Disease Registry.
  • CLL starting any line of chemo
  • Must be enrolled within 2 months of starting new chem.
  • Able to speak and read English
  • Able to fill out questionnaires every 3 months
  • (patient receives a $10 Visa gift card for every questionnaire)



A Randomized, Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate resistant Prostate Cancer.
  • Must have progressive measurable disease, or bone scan progression or increasing PSA while on or after androgen ablative therapy.
  • Must be 28 days since completing radiation.
  • No other cytotoxic chemotherapy.
  • No brain mets.

EMR 62242-006:

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects with Asymptomic or Mildly Symptomatic Castrate-Resistant Prostate Cancer (mCROC).  
  • Radiological evidence and progression of bone lesions with or without soft tissue lesions.
  • Testosterone suppression ≤ 50ng/dL
  • ECOG < 2
  • No prior therapy
  • No brain mets


A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer.
  • Must be 18 years of age.
  • Subjects with advanced prostate cancer who will receive sipuleucel-T 

T-Cell Lymphoma

PTCL Registry:

Prospective, Longitudinal, Multinational Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma.
  • Newly diagnosed T-Cell lymphoma